Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
about
Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathwaysLeptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individualsFatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expressionShort-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.Morusin shows potent antitumor activity for human hepatocellular carcinoma in vitro and in vivo through apoptosis induction and angiogenesis inhibitionActivation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinomaRECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch.The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinomaYC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.[6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2.Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinomaAnti-angiogenic therapy: concept to clinic.Cellular and molecular mechanisms of hepatocellular carcinoma: an update.Novel inhibitors of signal transducer and activator of transcription 3 signaling pathway: an update on the recent patent literature.Emerging strategies for cancer immunoprevention.Promising new strategies for hepatocellular carcinoma.Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6.Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.STAT3 inhibition reduces toxicity of oncolytic VSV and provides a potentially synergistic combination therapy for hepatocellular carcinoma.Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathwaysTherapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma.Pneumatocele during sorafenib therapy: first report of an unusual complication.Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK
P2860
Q26783372-4FD4530E-479E-4EC5-91B7-D258471D7071Q26859118-F40953A7-BF3F-4274-8C57-B4FBBEA744EEQ28543028-0FD54510-DC10-4558-A91D-2720E7CC585BQ30240170-02A98D2A-93A2-482F-BA2D-6B87497E04C7Q30964683-391E700A-F493-429F-B408-B202744C8E30Q33826039-36A57AE9-0FCA-46C4-90A0-EDDC06A490B5Q34200875-028F1D7F-6C2E-4C7B-A115-01237A65CE07Q34877852-E6DE56B2-5DC0-4AC5-8E37-83FF8F5F5649Q35130808-76FED70C-5594-446C-B233-41F970ACA9A0Q35232168-41AF7EE1-DC29-4F11-A4DF-3666FA234E3BQ36890491-131A7852-E4A5-4209-97E4-0AEEAA6E2C36Q37049104-572980D7-AFF4-49E2-BAF3-3575601A59A6Q37493227-BA3426EF-3AAF-4420-856A-FD65F3B434D8Q37616069-39A8A0D5-A30F-4C00-B554-3398CE76EB78Q37696388-9C1BFE77-3B66-4455-A478-CD0F67D77E09Q37955304-740167B5-3CF7-44BA-AF30-339D02E00D7AQ38046107-43AE5F22-FB80-4AB2-8B48-CC45116458B1Q38179031-9A7E2D0D-0815-469F-B734-74358309C4B5Q38585850-7AEC79A7-B0E3-4F74-A3AA-276C1F2DEDDAQ38936589-A7934726-341B-432C-87DC-FC3D96214DD1Q38979718-D77557C0-4E87-4564-8031-617C814AC1B0Q39474625-1BED3DD8-ACB3-4455-A950-2B3ABA40B05CQ41506217-BBFFCF22-7260-4E87-AAAE-5AFAB5D57732Q41637262-B42B52FB-7D9C-4B77-A474-EE9AD9C97BEAQ42144822-F89D5DDD-2DA1-4DC4-A17C-517BB12F205DQ42181154-1D997CBE-FC3C-4F0D-9AB3-F99E214D2210Q47237374-2746BE5D-147D-4A45-B153-3E08AA72B540Q49787320-2E4004A3-3F1E-4939-92B9-4DA85ED75F22Q54198260-A40393F6-74D9-47D8-A41A-1873A6D4741AQ58800733-553A52A5-2040-4CFA-BC73-AF06EB39DC61
P2860
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
@ast
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
@en
type
label
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
@ast
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
@en
prefLabel
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
@ast
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
@en
P2093
P2860
P356
P1476
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
@en
P2093
Fang-Ming Gu
Jia-Hao Jiang
Jin-Feng Pan
Quan-Lin Li
Xiao-Yong Huang
P2860
P304
P356
10.3748/WJG.V17.I34.3922
P407
P577
2011-09-01T00:00:00Z